Rezdiffra (resmetirom) / Madrigal Pharma - LARVOL DELTA

Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial. (PubMed, J Hepatol) - P3 | "Resmetirom treatment led to significant improvements in qFC, qFS, and individual collagen features associated with fibrosis progression. These digital pathology findings support the antifibrotic efficacy of resmetirom and demonstrate the potential of AI-based quantification to help define the fibrogenic response in MASH."

Journal • P3 data • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD): Integrating metabolic and hepatic management into pharmacy practice. (PubMed, Am J Health Syst Pharm) - "As treatment options for MASLD continue to emerge, it is crucial for pharmacists across all practice settings to optimize patient care. Optimization should occur through early recognition and management of comorbidities and disease, as well as by ensuring access to medications. Effective management of MASLD involves collaboration among all members of the healthcare team to enhance patient outcomes and maintain safety."

Journal • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Neutrophil Extracellular Traps Prime B Cell–Mediated Fibrogenesis in MASH by Silencing HES1 and Promoting Plasma Cell Differentiation (IMMUNOLOGY 2026) - "Although the FDA-approved Resmetirom shows promise in reversing MASLD, its efficacy in advanced fibrosis remains limited... NETs promote B-cell–mediated fibrogenesis in MASH by silencing HES1 and driving plasma-cell differentiation. Targeting NET-induced B-cell reprogramming offers a promising therapeutic strategy to limit liver inflammation and fibrosis in MASH."

Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Solid Tumor • HES1 • SDC1

AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update. (PubMed, Dig Liver Dis) - "Recent regulatory frameworks from FDA and EMA have accelerated therapeutic development, with Resmetirom and Semaglutide representing the first agents to achieve histological efficacy in Phase 3 trials for patients with MASH and F2-F3 fibrosis. Building upon these advances, the AISF STEPS-MASH framework provides a structured approach for the identification, selection, and monitoring of patients eligible for therapy. This position paper outlines evidence-based recommendations for the integration of emerging pharmacological strategies into clinical practice in Italy, emphasizing both high-risk and broader metabolic populations."

Journal • Review • Cardiovascular • Diabetes • Fibrosis • Genetic Disorders • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH). (PubMed, Drug Des Devel Ther) - "As semaglutide has now also gained regulatory approval for fibrotic MASH, optimal positioning of resmetirom within treatment algorithms, combination strategies with GLP-1 receptor agonists, and the long-term impact on liver-related and cardiometabolic outcomes remain key priorities. This review discusses the evidence supporting conditional approval of resmetirom, outlines current clinical recommendations, early real-world experiences, and highlights ongoing challenges and future directions in the management of fibrotic MASH."

Journal • Review • Addiction (Opioid and Alcohol) • Diabetes • Endocrine Disorders • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Dynamics of Noninvasive Tests, LIVERFASt (LFASt), FIB-4 and Vibration-Controlled Transient Elastography (VCTE, FibroScan), during Monitoring Therapy with THR-beta Agonist Resmetirom (RT) in Patients with MASH: Update (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Non-invasive • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Early Real-World Liver Biomarker Changes among Resmetirom-Treated MASH Patients, with and without Concomitant GLP-1 Use: A Descriptive Cohort Study (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Biomarker • Clinical • Real-world • Real-world evidence • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Early Real-World Liver Biomarker Changes among Resmetirom-Treated MASH Patients, with and without T2DM: A Descriptive Cohort Study (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Biomarker • Clinical • Real-world • Real-world evidence • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Type 2 Diabetes Mellitus

Evaluating the Effect of Resmetirom on Thyroid Function: A Post Hoc Analysis of MAESTRO-NASH, a Phase 3 Randomized Controlled Study in Patients with MASH and Fibrosis (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • P3 data • Retrospective data • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Synergistic Metabolic and Hepatic Benefits of Dorzagliatin and Resmetirom in MASLD Mice (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Preclinical • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

FDA-approved fatty liver drug also suppresses liver tumors in mice (Medical Xpress) - "The team discovered that Resmetirom, an FDA-approved drug for fatty liver disease, significantly reduces liver fat and inhibits tumor growth in preclinical experiments. The treatment was also found to lower MDK levels. When combined with MDK inhibitors, the drug demonstrates a synergistic anti-cancer effect, further improving liver metabolism, reducing liver fat, suppressing tumors, and modulating the immune microenvironment."

Preclinical • Hepatocellular Cancer

Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. (PubMed, Nat Rev Gastroenterol Hepatol) - "After decades of limited therapeutic options, pivotal developments, including the landmark FDA conditional approvals of resmetirom and semaglutide, mark a transformative era for metabolic dysfunction-associated steatohepatitis (MASH) management, with numerous additional promising treatments rapidly advancing through late-stage development...This Review synthesizes lessons learned from prior trials and critically appraises current and emerging drug classes. We propose a pragmatic, mechanism-aligned framework for personalized MASH care that integrates lifestyle intervention, incretin-based therapies and liver-directed agents, with the overarching objective of mitigating progression to liver-related complications while simultaneously addressing the excess cardiometabolic morbidity and mortality that characterize this multisystem disorder."

Journal • Review • Fibrosis • Hepatology • Immunology • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Mechanistic Study of Resmetirom in Treating MAFLD Mouse Model: Gut Microbiota Remodeling and Metabolic Regulation (APASL 2026) - No abstract available

Gut Microbiota • Preclinical • Metabolic Dysfunction-Associated Steatotic Liver Disease

Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma and mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression (APASL 2026) - No abstract available

Hepatocellular Cancer • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • Solid Tumor • LRP1

Transcriptomic analysis revealed distinct mechanisms underlying the synergistic effect of a fatty acid synthase inhibitor and resmetirom combination in LDL receptor knockout MASH mice (EASL 2026) - No abstract available

Omic analysis • Preclinical • Metabolic Dysfunction-Associated Steatohepatitis • FASN

Enhancing effects of combining resmetirom and semaglutide in a modified AMLN diet-induced mouse model for metabolic dysfunction-associated steatohepatitis (MASH) (EASL 2026) - No abstract available

Preclinical • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Modulation of interactions between mitochondria and the endoplasmic reticulum by resmetirom in MASLD (EASL 2026) - No abstract available

Metabolic Dysfunction-Associated Steatotic Liver Disease

Synergy of SOAT2-inhibitor PRD001 with resmetirom in reducing MASH and fibrosis in obese Ldlr-/-.Leiden mice (EASL 2026) - No abstract available

Preclinical • Fibrosis • Immunology • Metabolic Dysfunction-Associated Steatohepatitis • Obesity

Which comes first: GLP-1 RA vs resmetirom in MASH real world practice (EASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Metabolic Dysfunction-Associated Steatohepatitis

Early and Week 52 biomarker (MRI-PDFF, ALT, MRE and PRO-C3) responses to resmetirom predict improvements in MASH and liver fibrosis (EASL 2026) - No abstract available

Biomarker • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatohepatitis

Cost-effectiveness of resmetirom treatment, aligned with practice guidance, for suspected 'At-Risk MASH' identified by transient elastography without histologic confirmation (EASL 2026) - No abstract available

Cost effectiveness • HEOR • Metabolic Dysfunction-Associated Steatohepatitis

Timing and concordance of non-invasive treatment responses to Resmetirom in real-world practice (EASL 2026) - No abstract available

Clinical • Discordant • Non-invasive • Real-world • Real-world evidence • Metabolic Dysfunction-Associated Steatotic Liver Disease

Real-world effectiveness of one year of Resmetirom treatment in at-risk metabolic dysfunction–associated steatohepatitis (EASL 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Baseline ANTICIPATE score and response predicts liver outcome events in an 180 patient MASH cirrhosis cohort treated with resmetirom (EASL 2026) - No abstract available

Biomarker • Clinical • Fibrosis • Hepatology • Immunology • Metabolic Dysfunction-Associated Steatohepatitis

Evaluating non-invasive eligibility criteria for resmetirom in metabolic dysfunction-associated steatotic liver disease (MASLD): real-world data from an italian multicentric cohort (EASL 2026) - No abstract available

Clinical • Non-invasive • Real-world • Real-world evidence • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease